Injectable off-the-shelf cartilage, tendon, and ligament repair compositions and methods of use
Summary
The USPTO granted Patent US12595463B2 to EPIBONE, INC. covering injectable compositions comprising condensed mesenchymal cell bodies and hydrogels for cartilage, tendon, and ligament repair. The patent includes 11 claims and covers methods of treating connective tissue defects and cartilage injuries using cell-based therapies.
What changed
The USPTO issued Patent US12595463B2 granting EPIBONE exclusive rights to compositions combining condensed mesenchymal cell bodies with hydrogels for connective tissue repair. The compositions may incorporate drugs or growth factors and target progenitor cells capable of producing collagen and glycosaminoglycan extracellular matrices. This is a standard patent grant conferring enforceable IP rights to the assignee.
For biotechnology firms and medical device manufacturers developing cell-based or hydrogel-based therapies for musculoskeletal applications, this patent establishes IP barriers that may require licensing or design-around strategies. Healthcare providers and researchers working in regenerative medicine should be aware of the protected composition claims when developing similar treatment approaches.
What to do next
- Monitor patent portfolio for potential licensing needs
- Review freedom-to-operate for cell-based musculoskeletal therapies
- Assess applicability to product development pipeline
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Injectable off-the-shelf cartilage, tendon, and ligament repair compositions and methods of use
Grant US12595463B2 Kind: B2 Apr 07, 2026
Assignee
EPIBONE, INC.
Inventors
Sarindr Bhumiratana, Terri-Ann Kelly, Eric Meade Jeffries, Olivia Spencer Beane, Angela Hai Huang
Abstract
Compositions comprising a condensed mesenchymal cell body and a hydrogel are provided. The compositions may further include drugs or growth factors. The condensed mesenchymal cell body may include a connective tissue cell, or even a progenitor cell capable of producing connective tissue extracellular matrices such collagen and glycosaminoglycan. Also provided are methods of treating connective tissue defects, cartilage injury, and cartilage degradation.
CPC Classifications
C12N 5/0068 C12N 5/0655 C12N 5/066 A61K 9/0019 A61K 9/06 A61K 9/5031 A61K 31/726 A61K 38/1841 A61K 38/39 A61L 27/18 A61L 27/20 A61L 27/24 A61L 27/3654 A61L 27/3662 A61L 27/3852 A61L 27/386 A61L 27/52 A61L 27/54 A61L 2400/06 A61L 2430/06
Filing Date
2022-04-08
Application No.
17716029
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.